心肌重构分子机制解析

引用本文: 王立英, 张馨予, 刘家铭, 吴昕嵘, 张广超, 杨明硕, 周阳, 张艳琦. 心肌重构分子机制解析[J]. 分析化学, 2022, 50(5): 711-719. doi: 10.19756/j.issn.0253-3820.210856 shu

Citation: WANG Li-Ying, ZHANG Xin-Yu, LIU Jia-Ming, WU Xin-Rong, ZHANG Guang-Chao, YANG Ming-Shuo, ZHOU Yang, ZHANG Yan-Qi. Analysis of Molecular Mechanism of Myocardial Remodeling[J]. Chinese Journal of Analytical Chemistry, 2022, 50(5): 711-719. doi: 10.19756/j.issn.0253-3820.210856 shu

心肌重构分子机制解析

王立英 ^1, ,
张馨予 ^3, ,
刘家铭 ^1, ,
吴昕嵘 ^1, ,
张广超 ^1, ,
杨明硕 ^1, ,
周阳 ^1, ,
张艳琦 ^{2,
,}

1.
北华大学基础医学院, 吉林 132013;
2.
中国标准化研究院, 北京 100191;
3.
兰州大学化学化工学院, 兰州 730000

通讯作者: 张艳琦,E-mail:zhangyq@cnis.gov.cn

基金项目:
吉林省教育厅"十三五"科学技术研究项目（No.JJKH20220067KJ）、吉林省科技发展计划项目（No.20190303038SF）、吉林市科技发展计划项目（No.20190302018）和吉林省卫生健康委员会项目（No.2019J051）资助。

摘要: 考察了在体及离体情况下多种信号分子在心肌重构（Myocardial remodeling，MR）中的作用，并基于多种检测技术探讨了其作用机制。首先应用异丙肾上腺素（Isoprenaline，Iso）建立了Wistar大鼠MR的在体模型，并通过血管紧张素Ⅱ（AngiotensinⅡ，AngⅡ）诱导新生乳鼠心肌成纤维细胞（Myocardial fibroblasts，myoFbs）增殖，导致心肌纤维化（Myofibrosis，MF），从而建立了MR离体模型。进一步，基于Western blot技术进行相关蛋白表达检测以及甲基偶氮唑盐（Methyl thiazolyl tetrazolium，MTT）法进行的体外myoFbs增殖检测，结果表明，Iso可明显增加心肌组织中羟脯氨酸（Hydroxyproline，Hyp）含量和蛋白激酶Cα（Protein kinase Cα，PKCα）的表达。研究发现，10^-7 mol/L AngⅡ即可显著促进myoFbs增殖；进一步应用免疫细胞化学染色及激光共聚焦显微镜方法进行p-PKCα、细胞外信号调节蛋白激酶（Extracellular signal regulated protein kinases，ERKl/2）及活性氧（Reactive oxygen species，ROS）在myoFbs中的表达及含量检测，结果表明，MR的形成与ROS、p-PKCα和p-ERKl/2表达量增多有关。

关键词:

English

Analysis of Molecular Mechanism of Myocardial Remodeling

1.
Basic Medicine College of Beihua University, Jilin 132013, China;
2.
Chinese Institute of Standardization, Beijing 100191, China;
3.
College of Chemistry&Chemical Engineering, Lanzhou University, Lanzhou 730000, China

Corresponding author: ZHANG Yan-Qi, zhangyq@cnis.gov.cn

Received Date: 23 November 2021
Revised Date: 31 December 2021
Fund Project:
Supported by the Science and Technology Research Project of the Department of Education of Jilin Province (No.JJKH20220067KJ), the Science and Technology Development Plan Project of Jilin Province (No.20190303038SF), the Science and Technology Development Project of Jilin City (No.20190302018) and the Jilin Provincial Health Technology Innovation Project (No.2019J051).

Abstract: The roles of various signaling molecules in myocardial remodeling (MR) in vivo and in vitro were investigated and the mechanisms based on the combination of various detection techniques was explored in this study. First, the in vivo MR model of Wistar rat was established using isoprenaline (Iso). AngiotensinⅡ (AngⅡ) induced proliferation of neonatal rat myofibroblasts (myoFbs) and thus set up the MR model in vitro. Further, Western blot was applied to detection of the expression of PKCα (protein kinase Ca, PKCα) in vivo, while methyl thiazolyl tetrazolium (MTT) assay was adopted for detection of myoFbs proliferation in vitro. Iso increased both the content of hydroxyproline (Hyp) and the expression of PKCα in myocardial tissue significantly. At the same time, it was found that AngⅡ (10^-7 mol/L) promoted the proliferation of myoFbs significantly. Immunocytochemical staining and laser confocal microscopy were used to detect expression and content of p-PKCα, extracellular signal regulating protein kinase (ERKl/2) and reactive oxygen species (ROS) induced by AngⅡ in myoFbs. The results showed that the formation of MR was related to the increase of expression of ROS, p-PKCα and p-ERKl/2.

Key words:

1. [1]
  SUN Jian-Qi, MA Li-Kun. Adv. Cardiovasc. Dis., 2008, 29(5):704-706. 孙建琦, 马礼坤. 心血管病学进展, 2008, 29(5):704-706.
2. [2]
  NI Y J, DENG J, LIU X, LI Q, ZHANG J L, BAI H Y, ZHANG J W. J. Cell Mol. Med., 2020, 25(1):203-216.NI Y J, DENG J, LIU X, LI Q, ZHANG J L, BAI H Y, ZHANG J W. J. Cell Mol. Med., 2020, 25(1):203-216.
3. [3]
  MAO Huan-Hao, YE Jian-Fei, ZHENG Wei-Feng, YANG Ying. Chin. J. Gen. Pract., 2021, 19(11):1861-1863. 茅焕豪, 叶剑飞, 郑伟峰, 杨莹. 中华全科医学, 2021, 19(11):1861-1863.
4. [4]
  WANG Hao, ZHANG Zhen-Xian. Inf. Tradit. Chin. Med., 2021, 38(8):70-74. 王浩, 张振贤. 中医药信息, 2021, 38(8):70-74.
5. [5]
  WU Q Q, XIAO Y, YUAN Y, MA Z G, LIAO H H, LIU C, ZHU J X, YANG Z, DENG W, TANG Q Z. Clin. Sci., 2017, 131(18):2319-2345.WU Q Q, XIAO Y, YUAN Y, MA Z G, LIAO H H, LIU C, ZHU J X, YANG Z, DENG W, TANG Q Z. Clin. Sci., 2017, 131(18):2319-2345.
6. [6]
  YU Ya. Chin. Pharmacol. Bull., 2017, 33(6):863-868. 余娅. 中国药理学通报, 2017, 33(6):863-868.
7. [7]
  LIU S Z, HE Y, SHI J, LIU L L, MA H, HE L, GUO Y Q. J. Cell. Biochem., 2019, 120(8):13226-13236.LIU S Z, HE Y, SHI J, LIU L L, MA H, HE L, GUO Y Q. J. Cell. Biochem., 2019, 120(8):13226-13236.
8. [8]
  YANG Ming, DONG Zhu-Qin, LUO Ying, SUN Zhi-Qiang, LIN Dong-Ming, HUANG Shu-Wei. J. Chin. Med. Western Med., 2019, 29(6):442-445. 杨明, 董竹琴, 罗颖, 孙志强, 林冬铭, 黄抒伟. 中西医结合杂志, 2020, 29(6):442-445.
9. [9]
  ZHENG X, YANG K, ZHANG H, DONG W, PENG W, ZHAO Y. Exp. Anim., 2020, 45(6):113-122.ZHENG X, YANG K, ZHANG H, DONG W, PENG W, ZHAO Y. Exp. Anim., 2020, 45(6):113-122.
10. [10]
  YANG Guang, XIA Ru-Jie, HE Yang, ZHANG Wei, SHI Yong, WANG Lan. Chin. J. Geriatr. Heart, Brain Vessel Dis., 2021, 23(10):1019-1022. 杨光, 夏汝杰, 何杨, 张伟, 施勇, 王岚. 中华老年心脑血管病杂志, 2021, 23(10):1019-1022.
11. [11]
  WANG Li-Ying, SU Hai-Yan, WANG Xuan, ZHOU Yan, YANG Shi-Jie. Chin. J. Anal. Chem., 2015, 43(12):1870-1875. 王立英, 苏海燕, 王璇, 周艳, 杨世杰. 分析化学, 2015, 43(12):1870-1875.
12. [12]
  WANG Li-Ying, SU Hai-Yan, LI Chun-Ying, WU Dian-Xiu, LIU Nan-Nan. J. Beihua Univ., 2016, 17(2):200-204. 王立英, 苏海燕, 李春颖, 吴殿秀, 刘楠楠. 北华大学学报, 2016, 17(2):200-204.
13. [13]
  WANG L Y, LI H, YANG S J. Chem. Res. Chin. Univ., 2012, 28(1):84-90.WANG L Y, LI H, YANG S J. Chem. Res. Chin. Univ., 2012, 28(1):84-90.
14. [14]
  WANG L Y, LI H, YANG S J, GUAN F Y. African J. Pharm. Pharmacol., 2012, 29(7):2100-2011.WANG L Y, LI H, YANG S J, GUAN F Y. African J. Pharm. Pharmacol., 2012, 29(7):2100-2011.
15. [15]
  KUMAR U, WETTERSTEN N, GARIMELLA P S. Cardiol. Clin., 2019, 37(3):251-265.KUMAR U, WETTERSTEN N, GARIMELLA P S. Cardiol. Clin., 2019, 37(3):251-265.
16. [16]
  WANG Li-Ying, BIAN Liang-Qi, SU Xiao-Wei, SU Hai-Yan, LIU Xu, LIU Nan-Nan. Chin. J. Anal. Chem., 2019, 47(2):256-261. 王立英, 卞良奇, 苏小伟, 苏海燕, 刘絮, 刘楠楠. 分析化学, 2019, 47(2):256-261.
17. [17]
  ZHANG Xing-Guang, YI Gui-Yan, LYU Xiao-Feng, LIU Han-Ju, XU Xiu-Ping, JIAO Xiu-Min. Chin. J. Anal. Chem., 2012, 40(6):955-959. 张星光, 依桂艳, 吕肖锋, 刘汉菊, 许秀萍, 焦秀敏. 分析化学, 2012, 40(6):955-959.

扫一扫看文章

计量

PDF下载量: 0
文章访问数: 29
HTML全文浏览量: 3

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

心肌重构分子机制解析

通讯作者: 张艳琦,E-mail:zhangyq@cnis.gov.cn

English

Analysis of Molecular Mechanism of Myocardial Remodeling

Corresponding author: ZHANG Yan-Qi, zhangyq@cnis.gov.cn

CCS Chemistry：嵌段共聚物自组装成 “三明治”二维有机材料，实现纳米级压力传感功能

CCS Chemistry：颜徐州、鲍哲南：你的皮肤可能是一片SPMs

CCS Chemistry：工作高效不疲劳，只须让催化剂动起来

CCS Chemistry：静电组装导向聚合- 聚电解质纳米凝胶量化制备新策略

CCS Chemistry：金黄色葡萄球菌醛基脱氢酶是如何识别特异性底物的？

计量

通讯作者: 陈斌, bchen63@163.com

中国化学会秘书处

心肌重构分子机制解析

通讯作者: 张艳琦,E-mail:zhangyq@cnis.gov.cn

English

Analysis of Molecular Mechanism of Myocardial Remodeling

Corresponding author: ZHANG Yan-Qi, zhangyq@cnis.gov.cn

CCS Chemistry：嵌段共聚物自组装成 “三明治”二维有机材料，实现纳米级压力传感功能

CCS Chemistry：颜徐州、鲍哲南： 你的皮肤可能是一片SPMs

CCS Chemistry：工作高效不疲劳，只须让催化剂动起来

CCS Chemistry：静电组装导向聚合- 聚电解质纳米凝胶量化制备新策略

CCS Chemistry：金黄色葡萄球菌醛基脱氢酶是如何识别特异性底物的？

计量

文章相关

通讯作者: 陈斌, bchen63@163.com

中国化学会秘书处

CCS Chemistry：颜徐州、鲍哲南：你的皮肤可能是一片SPMs